GPT Healthcare demonstrates robust profit growth, as evidenced by a TTM Compounded Profit Growth of 102%. This indicates a strong ability to increase profitability. However, sales growth shows a 39% TTM. While still positive, it is less impressive than the profit growth, suggesting potential areas for improvement in revenue generation.

This profit growth outpaces sales growth, highlighting enhanced efficiency in converting sales into profits. This indicates management's effectiveness in controlling costs and optimizing operations. Sustaining these growth rates will be crucial for maintaining investor confidence and supporting future expansion.

GPT Healthcare exhibits strong capital efficiency and returns. The ROCE stands at 32.61%, reflecting effective utilization of capital employed to generate profits. ROE is also robust at 24.89%, indicating efficient use of shareholder funds.

These figures suggest that the company is adept at generating returns for its investors. This level of capital efficiency is a positive indicator of management's ability to allocate resources effectively and drive profitability.

GPT Healthcare's financial health presents a mixed picture. The company's dividend payout has been increasing, with the dividend payout % at 115% in Mar 2022, which is greater than 100% suggesting that the company is paying out more in dividends than it is earning in profit.

This raises concerns about the long-term sustainability of such high payouts. While rewarding shareholders is important, consistently high payouts, especially when exceeding net profits, could strain the company's financial resources. This could impact its ability to reinvest in growth opportunities or weather potential downturns.

GPT Healthcare's shareholding pattern reveals some shifts that warrant attention. Promoter holding remains stable at 65.57%, indicating continued confidence from the company's founders. However, there has been a decrease in FII holding from 6.68% in Mar 2024 to 4.49% in Mar 2025.

This decline could signal a decrease in institutional investor confidence, potentially due to concerns about growth prospects or other financial metrics. Monitoring these trends is important to understand the long-term implications for the company's stock performance and overall stability.

There is no specific data available on off-balance sheet exposure quantification.

There is no specific data available on contingent liability evaluation.

There is no specific data available on accounting quality red flags.